The human papillomavirus (HPV) is the causative agent for cervical cancer, which is one of the leading causes of gynaecologic cancer in developing countries (1). Cervical cancer is a significant cause of morbidity and mortality in these countries. Globally, there are about 500 000 new cases with about 270 000 deaths per year, the majority of which are in developing countries (1, 2). In addition to cervical cancer, HPV infection has been associated with a number of other cancers and non-cancerous conditions in both men and women (3).
This manuscript has been assigned to a volume and issue but has not yet been published. It is either being edited, typeset or is in the proof stage of publication.
In the pre-published stage, this manuscript may contain statements, opinions, and information that have errors in facts, figures, or interpretation. Any final changes in this manuscript will be made at the time of publication and will be reflected in the final electronic version of the issue. The editors and authors and their respective employees are not responsible or liable for the use of any such inaccurate or misleading data, opinion or information contained in the articles in this section.